+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells



Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells



Cancer Research 64(7): 2509-2515



Tumor progression due to loss of autocrine negative transforming growth factor-beta (TGF-beta) activity was reported in various cancers of epithelial origin. Estrogen receptor expressing (ER(+)) breast cancer cells are refractory to TGF-beta effects and exhibit malignant behavior due to loss or inadequate expression of TGF-beta receptor type II (RII). The exogenous TGF-beta effects on the modulation of cell cycle machinery were analyzed previously. However, very little is known regarding the endogenous control of cell cycle progression by autocrine TGF-beta. In this study, we have used a tetracycline regulatable RII cDNA expression vector to demonstrate that RII replacement reconstitutes autocrine negative TGF-beta activity in ER(+) breast cancer cells as evidenced by the delayed entry into S phase by the RII transfectants. Reversal of the delayed entry into S phase by the RII transfectants in the presence of tetracycline in addition to the decreased steady state transcription from a promoter containing the TGF-beta responsive element (p3TP-Lux) by TGF-beta neutralizing antibody treatment of the RII transfected cells confirmed that autocrine-negative TGF-beta activity was induced in the transfectants. Histone H1 kinase assays indicated that the delayed entry of RII transfectants into phase was associated with markedly reduced cyclin-dependent kinase (CDK)2 kinase activity. This reduction in kinase activity was due to the induction of CDK inhibitors p21/waf1/cip1 and p27/kip, and their association with CDK2. Tetracycline treatment of RII transfectants led to the suppression of p21/waf1/cip1and p27/kip expression, thus, directly demonstrating induction of CDK inhibitors by autocrine TGF-beta leading to growth control of ER(+) breast cancer cells.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 012035927

Download citation: RISBibTeXText

PMID: 15059906


Related references

Endogenous Control of Cell Cycle Progression by Autocrine Transforming Growth Factor in Breast Cancer Cells. Cancer Research 64(7): 2509-2515, 2004

Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Cell Growth and Differentiation 1(8): 367-374, 1990

Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells. Journal of Biological Chemistry 277(29): 26662-26672, 2002

Autocrine and exogenous transforming growth factor beta control cell cycle inhibition through pathways with different sensitivity. Journal of Biological Chemistry 279(38): 40237-40244, 2004

Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Research 54(22): 5867-5874, 1994

Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer. Breast Cancer Research 2(2): 116-124, 2000

Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. Journal of Clinical Investigation 92(6): 2569-2576, 1993

Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Research 48(14): 3898-3904, 1988

Autocrine human growth hormone inhibits placental transforming growth factor-b gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells. The Journal of Biological Chemistry 277(29): 662-72, 2002

Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Molecular and Cellular Biology 11(10): 5032-5043, 1991

Altered expression of transforming growth factor-alpha and transforming growth factor-beta autocrine loops in cancer cells. Heppner, G H Advances in Molecular and Cell Biology; Biology of the cancer cell 35-59, 1993

Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of alpha transforming growth factor epidermal growth factor epidermal growth factor receptor c fos and c myc genes. Proceedings of the American Association for Cancer Research Annual Meeting 32: 209, 1991

Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. Journal of Biological Chemistry 272(19): 12862-7, 1997

Repression of autocrine transforming growth factor beta 1 and beta 2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth and Differentiation 4(2): 115-123, 1993

Expression of transforming growth factor-beta (TGF-beta) receptors, TGF-beta 1 and TGF-beta 2 production and autocrine growth control in osteosarcoma cells. International Journal of Cancer 58(3): 440-445, 1994